Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Contineum Therapeutics, Inc. Class A ( (CTNM) ) is now available.
On September 18, 2025, Contineum Therapeutics announced positive topline data from its Phase 1b PET trial of PIPE-791, demonstrating high brain receptor occupancy in healthy volunteers and progressive multiple sclerosis patients. The trial confirmed a pharmacokinetic relationship between PIPE-791 exposure and LPA1 receptor engagement, supporting the planned doses for future Phase 2 trials to exceed 90% target coverage with once daily dosing, potentially advancing the company’s position in the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis.
The most recent analyst rating on (CTNM) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.
Spark’s Take on CTNM Stock
According to Spark, TipRanks’ AI Analyst, CTNM is a Underperform.
Contineum Therapeutics, Inc. receives a low stock score due to significant financial struggles, including a lack of revenue and negative profitability. The technical analysis reveals a bearish trend, and the valuation is weak with a negative P/E ratio. While there are some positives in terms of debt reduction and cash reserves, these are overshadowed by the company’s operational challenges and weak market momentum.
To see Spark’s full report on CTNM stock, click here.
More about Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with significant unmet needs. The company is advancing a pipeline of internally-developed programs, including PIPE-791, an LPA1 receptor antagonist for idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain, and PIPE-307, a selective inhibitor of the M1 receptor for relapsing-remitting multiple sclerosis and major depressive disorder.
Average Trading Volume: 275,285
Technical Sentiment Signal: Buy
Current Market Cap: $347.4M
For detailed information about CTNM stock, go to TipRanks’ Stock Analysis page.